옵션 체인은 다양한 행사가격과 만기일에 대한 Tonix Pharmaceuticals의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Tonix Pharmaceuticals에 대한 시장 심리를 평가합니다..

Tonix Pharmaceuticals (NASDAQ:TNXP) 주식, 옵션 체인

Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals Holding Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares have surged 115% to $16.85 since Monday's open, driven by a series of key business updates this week.
What To Know: Tonix this week <a href="https://www.benzinga.com/pressreleases/25/03/g44104557/tonix-pharmaceuticals-presented-data-and-analyses-of-tnx-102-sl-treatment-effects-on-fibromyalgia-">announced data</a> regarding its fibromyalgia treatment, TNX-102 SL, presenting Phase 3 data at the 7th International Congress on Controversies in Fibromyalgia. 
The study showed that the sublingual formulation demonstrated a statistically significant improvement in the primary endpoint of reduction in fibromyalgia pain reduced pain. The U.S. FDA has set an August 15, 2025, Prescription Drug User Fee Act (PDUFA) goal date for potential marketing approval.
Tonix also announced the appointment of Siobhan Fogarty as Chief Technical Officer and <a href="https://www.benzinga.com/pressreleases/25/03/g44137620/tonix-pharmaceuticals-to-present-at-the-2025-virtual-investor-summit">confirmed</a> COO Jessica Morris will present at the 2025 Virtual Investor Summit on March 11.
Read Also: <a href="https://www.benzinga.com/news/global/25/03/44166916/whats-going-on-with-alibaba-stock-thursday-6">What&#8217;s Going On With Alibaba Stock Thursday?</a>
<h2 class="wp-block-heading">How To Buy TNXP Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Tonix Pharmaceuticals&#8217; case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, TNXP has a 52-week high of $1,216.00 and a 52-week low of $6.76.

News

TNXP

Tonix Pharmaceuticals (TNXP) Stock Is Up 115% This Week: What's Going On?

<ul>
<li>TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia</li>
<li>TNX-102 SL demonstrated statistically significant improvement in the primary endpoint of reduction in fibromyalgia pain in two double-blind randomized Phase 3 studies</li>
<li>FDA Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia</li>
<li>If approved by FDA, it would become the first member of a new class of non-opioid analgesic drugs for fibromyalgia and the first new drug for treating fibromyalgia in more than 15 years</li>
</ul>

Tonix Pharmaceuticals Presents Phase 3 Data On TNX-102 SL For Fibromyalgia At International Congress

Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares are moving higher on Friday after the company provided preliminary 2024 <a href="https://www.benzinga.com//node/43559033">fiscal-year financial results</a>.
What To Know: The company reported net revenue of $10.1 million, compared to $7.8 million for the prior year. In addition, it reported $98.8 million in cash and cash equivalents as of the end of 2024.
Tonix expects its cash reserves, along with approximately $30.4 million in gross proceeds from 2025 first-quarter sales, to sustain operations through the 2026 first quarter. The cash runway is expected to cover operations past the Food and Drug Administration&#8217;s August 15th goal date for a decision on marketing authorization for TNX-102 SL for fibromyalgia management. The company is now debt-free after repaying a mortgage with JGB Capital on February 3.
 Additionally, it reported capital expenditures of $0.1 million, compared $29.1 million for the prior year.
Lastly, Tonix reported a net operating loss of $126.6 million, compared to a net operating loss of $116.7 million for the prior year.
See Also: <a href="https://www.benzinga.com/25/02/43564020/consumer-sentiment-sinks-economist-flags-unusually-large-rise-in-inflation-perception">Consumer Sentiment Sinks In February: Economist Flags &#8216;Unusually Large&#8217; Rise In Inflation Perception</a>
TNXP Price Action: At the time of writing, Tonix shares are trading 14.8% higher at $12.90, per data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: via Shutterstock

Movers

What's Going On With Tonix Pharmaceuticals Shares Friday?

WIIM

Tonix Pharmaceutical shares are trading higher after the company provided preliminary Q4 financial results.

Preliminary Full Year 2024 Financial Results1
<ul>
<li>The Company had approximately $98.8 million in cash and cash equivalents as of December 31, 2024.</li>
<li>Net cash used in operating activities was approximately $60.9 million, compared to $102.0 million for the prior year.</li>
<li>Capital expenditures was approximately $0.1 million, compared to $29.1 million for the prior year.</li>
<li>Net operating loss was approximately $126.6 million, which includes non-cash impairment charges of approximately $59.0 million, compared to net operating loss of $116.7 million for the prior year.</li>
<li>The Company announced that net revenue from the sale of its marketed products was approximately $10.1 million, compared to $7.8 million for the prior year.</li>
<li>On February 3, 2025, the Company repaid a mortgage (Loan and Guaranty Agreement) with JGB Capital and related parties that was secured by two facilities and the Company is now debt-free.</li>
</ul>
The Company expects that its cash resources at December 31, 2024, and the gross proceeds of approximately $30.4 million raised from sales under its at-the-market facility in the first quarter of 2025, will be sufficient to fund its planned operations into the first quarter of 2026.

Earnings

Guidance

Tonix Pharmaceuticals Reports FY24 Preliminary Financials: $98.8M In Cash And Cash Equivalents As Of December 31, 2024, Revenue Hits ~$10.1M Vs $7.8M YoY

Biotech

General

Tonix Pharmaceuticals Announces Topline Results For Phase 1 Trial Of TNX-1500, Meeting Safety Objectives For Kidney Transplant Dosing Plan

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Shares of Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) rose sharply in today's pre-market trading following better-than-expected <a href="https://in.benzinga.com/news/earnings/25/02/43449486/palantir-q4-earnings-revenue-beat-eps-beat-us-revenue-up-52-customer-count-up-43-strong-guidance-this-is-a-new-phase-unlike-anything-that-has-come-before">fourth-quarter results</a>.
Palantir reported fourth-quarter revenue of $827.52 million, beating the consensus estimate of $775.91 million. The company reported fourth-quarter adjusted earnings of 14 cents per share, beating analyst estimates of 11 cents per share.
Palantir Technologies shares jumped 16.5% to $97.56 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Evaxion Biotech A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) gained 72.5% to $4.14 in pre-market trading.</li>
<li>Kairos Pharma, Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#NYSE">KAPA</a>) rose 40.1% to $2.13 in pre-market trading after jumping more than 6% on Monday.</li>
<li>Azitra, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#NYSE">AZTR</a>) gained 40% to $0.3900 in pre-market trading after gaining around 15% on Monday.</li>
<li>Invivyd, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) gained 27.4% to $1.35 in pre-market trading. Invivyd shares jumped 196% on Monday after the company provided preliminary fourth-quarter PEMGARDA net product revenue results.</li>
<li>CleanCore Solutions, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZONE#NYSE">ZONE</a>) shares jumped 25.5% to $1.28 in pre-market trading following a 3% gain on Monday.</li>
<li>Reborn Coffee, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REBN#NASDAQ">REBN</a>) rose 17.8% to $6.00 in pre-market trading after jumping 54% on Monday. Reborn Coffee recently announced it approve a franchisor in the U.S. and is intending to expand across the country.</li>
<li>American Rebel Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) shares climbed 16% to $1.38 in pre-market trading.</li>
<li>Tempus AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) gained 8% to $66.44 in pre-market trading. Tempus AI, Inc. announced it has completed its acquisition of Ambry Genetics.</li>
<li>XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) rose 7% to $16.79 in pre-market trading after adding 3% on Monday. XPeng witnessed a jump of 268% year-over-year. The company delivered 30,350 vehicles last month, marking a drop of 17.3% from December.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Universe Pharmaceuticals INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares fell 28.2% to $0.3012 in pre-market trading after announcing Nasdaq delisting notice.</li>
<li>MDJM Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UOKA#NASDAQ">UOKA</a>) dipped 27.2% to $0.1730 in pre-market trading after jumping 83% on Monday.</li>
<li>E-Home Household Service Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EJH#NASDAQ">EJH</a>) fell 25% to $0.7652 in today's pre-market trading after gaining 34% on Monday.</li>
<li>BriaCell Therapeutics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCTX#NASDAQ">BCTX</a>) shares fell 22.6% to $3.90 in pre-market trading as the company priced its $3.05 million public offering of 762,500 common shares at $4/share.</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares tumbled 20.2% to $0.1555 in pre-market trading. Tonix Pharmaceuticals shares dipped over 54% on Monday after the company announced a 1-for-100 reverse stock split.</li>
<li>HCW Biologics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) fell 16.1% to $0.5335 in pre-market trading. HCW Biologics shares jumped 129% on Monday after the company announced FDA clearance for its Phase 1 trial of HCW9302.</li>
<li>XChange TEC.INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHG#NASDAQ">XHG</a>) fell 14.2% to $0.7166 in pre-market trading after declining around 4% on Monday.</li>
<li>UBS Group AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBS#NYSE">UBS</a>) fell 6.1% to $32.81 in pre-market trading. UBS Group reported stronger-than-expected earnings for its fourth quarter and disclosed a share buyback program of up to $3 billion.</li>
<li>Ponce Financial Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDLB#NASDAQ">PDLB</a>) declined 5.3% to $12.61 in pre-market trading.</li>
<li>Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) shares dipped 5.2% to $124.31 in pre-market trading after the Chinese Ministry of Commerce added the company, along with Calvin Klein owner PVH Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) to the unreliable entities list amid the ongoing trade war with the U.S..</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43432950/jim-cramer-appfolio-is-a-cheap-stock-dont-sell-this-tech-stock">Jim Cramer Says AppFolio Is A &#8216;Good One,&#8217; But Summit Therapeutics? &#8216;Can&#8217;t Go There&#8217;</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

AREB

AZTR

BCTX

EVAX

HCWB

ILMN

IVVD

KAPA

PDLB

PLTR

REBN

UOKA

XPEV

ZONE

Why Palantir Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket

U.S. stocks traded lower toward the end of trading, with the S&amp;P 500 falling around 0.5% on Monday.
The Dow traded down 0.09% to 44,506.60 while the NASDAQ dipped 0.91% to 19,449.55. The S&amp;P 500 also fell, dropping, 0.53% to 6,008.22.
Check This Out: <a href="https://www.benzinga.com/25/01/43388778/jim-cramer-autozone-is-a-great-stock-recommends-buying-this-energy-stock">Jim Cramer: AutoZone Is A &#8216;Great&#8217; Stock, Recommends Buying This Energy Stock</a>
Leading and Lagging Sectors Consumer staples shares surged by 0.7% on Monday.
In trading on Monday, information technology shares fell by 1.4%.
Top Headline
U.S. construction spending increased by 0.5% month-over-month to an annual rate of $2,192 billion in December following a revised 0.2% gain in November.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>HCW Biologics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares shot up 131% to $0.6431 after the company announced FDA clearance for its Phase 1 trial of HCW9302.</li>
<li>Shares of Triumph Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGI#NYSE">TGI</a>)got a boost, surging 34% to $25.14 after the company agreed to go private in a $3 billion deal backed by Warburg Pincus and Berkshire Partners.</li>
<li>GH Research PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHRS#NASDAQ">GHRS</a>) shares were also up, gaining 81% to $19.17 after the company&#8217;s inhalable depression treatment GH001 met the primary endpoint in its Phase 2b trial, showing symptom reduction.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Owens &amp; Minor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) shares dropped 32% to $9.68 after the company issued lower-than-expected fourth-quarter and FY24 preliminary revenue results.</li>
<li>Shares of Napco Security Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSSC#NASDAQ">NSSC</a>) were down 29% to $26.11 following second-quarter results.</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) was down, falling 55% to $0.1941. Tonix Pharmaceuticals announced a 1-for-100 reverse stock split, effective Feb. 5.</li>
</ul>
Commodities In commodity news, oil traded up 0.6% to $72.95 while gold traded up 0.8% at $2,857.30.
Silver traded up 0.8% to $32.530 on Monday, while copper rose 1% to $4.3195.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.87%, Germany's DAX 40 dipped 1.40% and France's CAC 40 declined 1.20%. Spain's IBEX 35 Index fell 1.32%, while London's FTSE 100 fell 1.04%.
Asia Pacific Markets
Asian markets closed lower on Monday, with Japan's Nikkei 225 dipping 2.66%, Hong Kong's Hang Seng Index fell 0.04% and India's BSE Sensex falling 0.41%.
Economics
<ul>
<li>U.S. construction spending increased by 0.5% month-over-month to an annual rate of $2,192 billion in December following a revised 0.2% gain in November.</li>
<li>The ISM manufacturing PMI for the US climbed to 50.9 in January versus a revised reading of 49.2 in December and topping estimates of 49.8.</li>
<li>The S&amp;P Global manufacturing PMI rose to 51.2 in January, versus a preliminary reading of 50.1 and compared to 49.4 in December.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43432854/how-to-earn-500-a-month-from-pepsico-stock-ahead-of-q4-earnings">How To Earn $500 A Month From PepsiCo Stock Ahead Of Q4 Earnings</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

GHRS

NSSC

Crude Oil Moves Higher; Owens & Minor Shares Plummet

U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 150 points on Monday.
The Dow traded down 0.33% to 44,398.37 while the NASDAQ dipped 1.36% to 19,360.28. The S&amp;P 500 also fell, dropping, 0.89% to 5,986.91.
Check This Out: <a href="https://www.benzinga.com/25/01/43388778/jim-cramer-autozone-is-a-great-stock-recommends-buying-this-energy-stock">Jim Cramer: AutoZone Is A &#8216;Great&#8217; Stock, Recommends Buying This Energy Stock</a>
Leading and Lagging Sectors Health care shares surged by 0.3% on Monday.
In trading on Monday, information technology shares fell by 1.7%.
Top Headline
The ISM manufacturing PMI for the US climbed to 50.9 in January versus a revised reading of 49.2 in December and topping estimates of 49.8.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>HCW Biologics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares shot up 112% to $0.59 after the company announced FDA clearance for its Phase 1 trial of HCW9302.</li>
<li>Shares of Triumph Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGI#NYSE">TGI</a>)got a boost, surging 34% to $25.19 after the company agreed to go private in a $3 billion deal backed by Warburg Pincus and Berkshire Partners.</li>
<li>GH Research PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHRS#NASDAQ">GHRS</a>) shares were also up, gaining 82% to $19.25 after the company&#8217;s inhalable depression treatment GH001 met the primary endpoint in its Phase 2b trial, showing symptom reduction.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Owens &amp; Minor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) shares dropped 25% to $10.67 after the company issued lower-than-expected fourth-quarter and FY24 preliminary revenue results.</li>
<li>Shares of Napco Security Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSSC#NASDAQ">NSSC</a>) were down 25% to $27.70 following second-quarter results.</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) was down, falling 49% to $0.2184. Tonix Pharmaceuticals announced a 1-for-100 reverse stock split, effective Feb. 5.</li>
</ul>
Commodities In commodity news, oil traded down 0.1% to $72.49 while gold traded up 0.7% at $2,853.30.
Silver traded down 0.4% to $32.150 on Monday, while copper fell 0.1% to $4.2755.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.83%, Germany's DAX 40 dipped 1.38% and France's CAC 40 declined 1.08%. Spain's IBEX 35 Index fell 1.32%, while London's FTSE 100 fell 1.04%.
Asia Pacific Markets
Asian markets closed lower on Monday, with Japan's Nikkei 225 dipping 2.66%, Hong Kong's Hang Seng Index fell 0.04% and India's BSE Sensex falling 0.41%.
Economics
<ul>
<li>U.S. construction spending increased by 0.5% month-over-month to an annual rate of $2,192 billion in December following a revised 0.2% gain in November.</li>
<li>The ISM manufacturing PMI for the US climbed to 50.9 in January versus a revised reading of 49.2 in December and topping estimates of 49.8.</li>
<li>The S&amp;P Global manufacturing PMI rose to 51.2 in January, versus a preliminary reading of 50.1 and compared to 49.4 in December.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43432854/how-to-earn-500-a-month-from-pepsico-stock-ahead-of-q4-earnings">How To Earn $500 A Month From PepsiCo Stock Ahead Of Q4 Earnings</a></li>
</ul>

Dow Falls 150 Points; ISM Manufacturing PMI Rises In January

U.S. stocks traded lower this morning, with the Nasdaq Composite dipping 1.5% on Monday.
Following the market opening Monday, the Dow traded down 0.63% to 44,262.92 while the NASDAQ dipped 1.50% to 19,334.02. The S&amp;P 500 also fell, dropping, 1.13% to 5,972.20.
Check This Out: <a href="https://www.benzinga.com/25/01/43388778/jim-cramer-autozone-is-a-great-stock-recommends-buying-this-energy-stock">Jim Cramer: AutoZone Is A &#8216;Great&#8217; Stock, Recommends Buying This Energy Stock</a>
Leading and Lagging Sectors Consumer staples shares surged by 0.4% on Monday.
In trading on Monday, information technology shares fell by 2%.
Top Headline
Tyson Foods Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) posted better-than-expected first-quarter FY25 earnings result.
The company reported first-quarter FY25 sales growth of 2.3% year-on-year to $13.62 billion, beating the analyst consensus estimate of $13.44 billion.
Adjusted EBITDA for the quarter increased 29.2% to $961 million. Adjusted EPS of $1.14 beat the consensus estimate of $0.88.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>HCW Biologics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares shot up 129% to $0.6377 after the company announced FDA clearance for its Phase 1 trial of HCW9302.</li>
<li>Shares of MDJM Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UOKA#NASDAQ">UOKA</a>)got a boost, surging 92% to $0.2490.</li>
<li>GH Research PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHRS#NASDAQ">GHRS</a>) shares were also up, gaining 78% to $18.82 after the company&#8217;s inhalable depression treatment GH001 met the primary endpoint in its Phase 2b trial, showing symptom reduction.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares dropped 55% to $0.1206.</li>
<li>Shares of Heramba Electric plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PITA#NASDAQ">PITA</a>) were down 51% to $0.4324.</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) was down, falling 46% to $0.2292. Tonix Pharmaceuticals announced a 1-for-100 reverse stock split, effective Feb. 5.</li>
</ul>
Commodities In commodity news, oil traded down 0.4% to $72.26 while gold traded up 0.9% at $2,861.10.
Silver traded up 0.4% to $32.390 on Monday, while copper rose 0.1% to $4.2815.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 1.5%, Germany's DAX 40 dipped 2.1% and France's CAC 40 declined 1.9%. Spain's IBEX 35 Index fell 2.1%, while London's FTSE 100 fell 1.5%.
Asia Pacific Markets
Asian markets closed lower on Monday, with Japan's Nikkei 225 dipping 2.66%, Hong Kong's Hang Seng Index fell 0.04% and India's BSE Sensex falling 0.41%.
Economics
<ul>
<li>U.S. construction spending increased by 0.5% month-over-month to an annual rate of $2,192 billion in December following a revised 0.2% gain in November.</li>
<li>The ISM manufacturing PMI for the US climbed to 50.9 in January versus a revised reading of 49.2 in December and topping estimates of 49.8.</li>
<li>The S&amp;P Global manufacturing PMI rose to 51.2 in January, versus a preliminary reading of 50.1 and compared to 49.4 in December.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/25/02/43432854/how-to-earn-500-a-month-from-pepsico-stock-ahead-of-q4-earnings">How To Earn $500 A Month From PepsiCo Stock Ahead Of Q4 Earnings</a></li>
</ul>

PITA

S&P 500 Down Over 1%; Tyson Foods Posts Upbeat Results

Tonix Pharmaceuticals shares are trading lower after the company announced a 1-for-100 reverse stock split.

Stock Split

Tonix Pharmaceuticals Announces 1-for-100 Reverse Stock Split, Effective Feb. 5

<h3>Gainers</h3>
<ul>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares rose 76.9% to $0.58 during Wednesday's pre-market session. The market value of their outstanding shares is at $20.3 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) stock rose 57.77% to $2.13. The market value of their outstanding shares is at $8.5 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) stock moved upwards by 28.32% to $0.99. The market value of their outstanding shares is at $2.2 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock increased by 16.41% to $1.56. The company's market cap stands at $6.0 million. </li>
<li>OKYO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKYO#NASDAQ">OKYO</a>) shares increased by 13.89% to $1.18. The market value of their outstanding shares is at $39.9 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) stock moved upwards by 11.95% to $0.52. The company's market cap stands at $96.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>IMAC Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) shares decreased by 26.2% to $0.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.8 million. </li>
<li>Zentalis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZNTL#NASDAQ">ZNTL</a>) shares decreased by 24.59% to $1.81. The company's market cap stands at $128.9 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock fell 19.3% to $0.05. The market value of their outstanding shares is at $5.1 million. </li>
<li>Pulmonx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) shares declined by 15.71% to $5.1. The company's market cap stands at $201.3 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock declined by 15.45% to $1.15. The market value of their outstanding shares is at $31.6 million. </li>
<li>Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) shares fell 10.55% to $19.26. The company's market cap stands at $21.8 billion. The company's, Q4 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BACK

EYEN

LUNG

OCEA

OKYO

SLXN

SXTP

TEVA

TRIB

ZNTL

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) stock rose 85.5% to $1.43 during Wednesday's pre-market session. The company's market cap stands at $3.2 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) stock increased by 22.22% to $1.65. The market value of their outstanding shares is at $6.5 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) stock increased by 12.54% to $0.52. The company's market cap stands at $96.7 million. </li>
<li>MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) stock rose 12.34% to $6.19. The company's market cap stands at $24.5 million. </li>
<li>MiMedx Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXG#NASDAQ">MDXG</a>) shares increased by 10.37% to $10.0. The market value of their outstanding shares is at $1.4 billion. </li>
<li>Design Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) stock rose 9.78% to $5.5. The company's market cap stands at $311.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Zentalis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZNTL#NASDAQ">ZNTL</a>) shares declined by 27.9% to $1.73 during Wednesday's pre-market session. The company's market cap stands at $123.2 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares fell 17.72% to $0.05. The company's market cap stands at $5.2 million. </li>
<li>IMAC Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) shares declined by 16.4% to $1.02. The company's market cap stands at $2.0 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) stock fell 16.29% to $0.35. The company's market cap stands at $2.8 million. </li>
<li>Pulmonx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) shares fell 15.71% to $5.1. The market value of their outstanding shares is at $201.3 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares declined by 11.98% to $8.75. The market value of their outstanding shares is at $6.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DSGN

INKT

MDXG

RNAZ

VTAK

<a href="https://www.manchestereveningnews.co.uk/news/health/new-case-mpox-detected-uk-30876004">https://www.manchestereveningnews.co.uk/news/health/new-case-mpox-detected-uk-30876004</a>
&nbsp;
A new case of Mpox has been confirmed in the UK, the UK Health Security Agency (UKHSA) has said.
The latest case of Clade Ib Mpox is the seventh confirmed case since October 2024 after a sixth patient <a href="https://www.manchestereveningnews.co.uk/news/uk-news/new-mpox-case-detected-uk-30823540">was admitted to hospital last week</a>.
<a href="https://www.gov.uk/government/news/ukhsa-detects-first-case-of-clade-ib-mpox?utm_medium=email&amp;utm_campaign=govuk-notifications-topic&amp;utm_source=d72f8bd1-0516-4336-9e7d-b4f8a791ba9a&amp;utm_content=immediately">The UKHSA says</a> the infected patient had recently travelled to Uganda and that the risk to the UK population "remains low". The UKHSA and <a href="https://www.manchestereveningnews.co.uk/all-about/nhs">NHS</a> says it will not be disclosing any further details about the infected person.
Professor Susan Hopkins, Chief Medical Adviser at UKHSA, said: "The risk to the UK population remains low. Close contacts have been identified and offered appropriate advice in order to reduce the chance of further spread."
Mpox, previously known as monkeypox, is a rare infection most commonly found in parts of central and east Africa.
There is currently community transmission of the virus in Uganda, which has so far recorded <a href="https://www.afro.who.int/countries/uganda/publication/mpox-outbreak-uganda-situation-update-22-january-2025">2,209 confirmed Mpox cases</a> and 13 deaths since July 2024.
The Clade Ib variant is a new form of the virus, the which the World Health Organisation (WHO) declared as a global health emergency in August.
WHO says common symptoms of Mpox include a skin rash or lesions which can last two to four weeks, as well as a fever, headache, muscle aches, back pain, low energy and swollen lymph nodes.
<a href="https://www.nhs.uk/conditions/mpox/">The NHS says</a> Mpox can be passed on from person to person through:
Close physical contact with Mpox blisters or scabs
Touching clothing, bedding or towels used by someone with Mpox
The coughs or sneezes of a person with Mpox when they're close to you

AEMD

APDN

CMRX

GOVX

MRNA

VRAX

"New Case Of Mpox Detected In The UK After 'Concerning' Surge In Cases In Uganda" - Manchester Evening News

Shares of Taiwan Semiconductor Manufacturing Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) rose sharply in today's pre-market trading after the company announced <a href="https://www.benzinga.com/quote/TSM">fourth-quarter results</a>.
Taiwan Semiconductor Mfg. said net profit climbed 57% year-over-year to a record T$374.68 billion ($11.38 billion).
TSMC shares gained 4.7% to $216.61 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>SOBR Safe, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) gained 83.1% to $1.63 in pre-market trading after gaining 8% on Wednesday.</li>
<li>Powell Max Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMAX#NASDAQ">PMAX</a>) gained 67.8% to $2.45 in pre-market trading after the company announced acquisition plans and is targeting firms with between $1 million and $5 million in revenue to expand into the Hong Kong and Asian financial communications market.</li>
<li>BioLineRx Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) rose 40.1% to $0.1458 in pre-market trading after dipping 15% on Wednesday. BioLineRx recently announced a $10 million registered direct offering.</li>
<li>Wheeler Real Estate Investment Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>) gained 39.3% to $3.28 in pre-market trading after falling 4% on Wednesday.</li>
<li>AEON Biopharma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEON#NYSE">AEON</a>) rose 22.5% to $0.1342 in pre-market trading after dipping 14% on Wednesday. AEON Biopharma recently announced closing of $20.0 million underwritten public offering</li>
<li>DouYu International Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOYU#NASDAQ">DOYU</a>) rose 17.4% to $14.43 in pre-market trading after the company named Ms. Simin Ren as co-CEO and announced a special cash dividend of $9.94/ADS.</li>
<li>BigBear.ai Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) gained 15.1% to $3.90 in pre-market trading after the company announced a chief executive transition. BigBear.ai has appointed Kevin McAleenan as CEO and a member of the company's board, effective as of Wednesday. McAleenan will replace Mandy Long, who is transitioning to an advisory role.</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) gained 12.8% to $0.2620 in pre-market trading.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) gained 10.3% to $12.74 in pre-market trading after surging 55% on Wednesday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Transcontinental Realty Investors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TCI#NYSE">TCI</a>) shares fell 31.8% to $19.01 in pre-market trading.</li>
<li>Algorhythm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIME#NASDAQ">RIME</a>) fell 20.3% to $0.04 in pre-market trading after dipping 35% on Wednesday.</li>
<li>GlucoTrack, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) dipped 20.3% to $0.0630 in pre-market trading following a 35% decline on Wednesday.</li>
<li>Sonim Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONM#NASDAQ">SONM</a>) declined 15.5% to $3.19 in pre-market trading. Sonim Technologies shares gained 10% on Wednesday after Orbic North America announced an agreement in principle to acquire a substantial equity ownership position in the company.</li>
<li>C&amp;F Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFFI#NASDAQ">CFFI</a>) shares fell 15.3% to $60.01 in pre-market trading.</li>
<li>SI-BONE, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>) fell 14.7% to $14.01 in pre-market trading after gaining 5% on Wednesday. SI-BONE recently reported preliminary fourth-quarter revenue results.</li>
<li>LuxUrban Hotels Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUXH#NASDAQ">LUXH</a>) shares dipped 12.9% to $0.5991 in pre-market trading. LuxUrban Hotels recently issued FY25 revenue guidance.</li>
<li>Sangoma Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANG#NASDAQ">SANG</a>) fell 12.1% to $6.19 in today's pre-market trading after gaining 5% on Wednesday.</li>
<li>ANI Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) shares tumbled 11.6% to $50.01 in pre-market trading. ANI Pharmaceuticals recently issued preliminary fourth quarter and 2024 financial results and preliminary 2025 outlook.</li>
<li>Silexion Therapeutics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) fell 11.3% to $1.38 in pre-market trading after the company announced the pricing of $5.0 million public offering.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42998360/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks Delivering High-Dividend Yields</a></li>
</ul>

AEON

ANIP

BBAI

BLRX

CFFI

DOYU

GCTK

LUXH

PMAX

QUBT

RIME

SANG

SIBN

SOBR

SONM

WHLR

Why Taiwan Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket

Tonix Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NYSE">TNXP</a>) short percent of float has risen 151.76% since its last report. The company recently reported that it has 4.00 million shares sold short, which is 2.14% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Tonix Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736451017_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tonix Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Tonix Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Tonix Pharmaceuticals's peer group average for short interest as a percentage of float is 4.81%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(TNXP) - Analyzing Tonix Pharmaceuticals's Short Interest

<h3>Gainers</h3>
<ul>
<li>Traws Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) stock moved upwards by 139.4% to $12.02 during Monday's pre-market session. The market value of their outstanding shares is at $36.3 million. </li>
<li>GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) stock increased by 86.24% to $3.25. The company's market cap stands at $7.2 million. </li>
<li>RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) shares moved upwards by 85.3% to $1.53. The company's market cap stands at $53.4 million. </li>
<li>Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) stock increased by 51.7% to $2.67. The market value of their outstanding shares is at $2.8 million. </li>
<li>Ikena Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKNA#NASDAQ">IKNA</a>) stock rose 23.22% to $1.91. The market value of their outstanding shares is at $92.1 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock moved upwards by 16.63% to $0.7. The market value of their outstanding shares is at $4.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares declined by 25.6% to $0.06 during Monday's pre-market session. The company's market cap stands at $6.6 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock declined by 23.08% to $0.7. The market value of their outstanding shares is at $2.6 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares declined by 18.87% to $2.58. The company's market cap stands at $2.1 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares fell 15.8% to $0.52. The company's market cap stands at $96.2 million. </li>
<li>Electromed (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELMD#AMEX">ELMD</a>) shares fell 13.42% to $24.01. The market value of their outstanding shares is at $203.0 million. </li>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares declined by 13.15% to $0.39. The company's market cap stands at $17.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ELMD

GTBP

HSDT

IKNA

PHIO

PTIX

RAPT

TRAW

12 Health Care Stocks Moving In Monday's Pre-Market Session

Press Releases

"Breakthrough Stocks to Watch: WATT, STEM, PNPN.V, NXU, REKR Powering Santa Rally Momentum, more inside!"

Tonix Pharmaceuticals to Present at Two Upcoming January Investor Conferences

Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Gary Ainsworth as Vice President of Market Access

Tonix Pharmaceuticals Announces 1-for-100 Reverse Stock Split

Management

Tonix Pharmaceuticals Promotes Siobhan Fogarty to Chief Technical Officer

Tonix Pharmaceuticals to Participate in the 2025 BIO CEO & Investor Conference

Tonix Pharmaceuticals Announces Positive Topline Results from Phase 1 Trial for TNX-1500, a Next Generation anti-CD40L mAb Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoimmune Diseases

Health Care

Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at 7th International Congress on Controversies in Fibromyalgia

Tonix Pharmaceuticals to Present at the 2025 Virtual Investor Summit

INTZ

KAVL

PNPNF

PRSO

REKR

STEM

TSXV:PNPN

WATT

Achilles Therapeutics plc - American Depositary Shares

Achilles Therapeutics

Agenus

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Aerovate Therapeutics, Inc. - Common Stock

Aerovate Therapeutics

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

BeyondSpring

Cibus

Cue Biopharma

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

iBio

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

IO Biotech

Kronos Bio

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

Mural Oncology

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

PMV Pharma

Pyxis Oncology

Quince Therapeutics

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Shattuck Labs

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

X4 Pharmaceuticals

Exagen

Alliance Global Partners

Dawson James

Noble Capital Markets

Untitled design - 2024-12-07T011441.837

Tonix&#39;s TNX 102-SL Could Offer New Hope Of Pain Relief Without Narcotics For Fibromyalgia Sufferers

Screenshot 2024-11-13 at 11.54.41 PM

ABBV

Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments

Screenshot 2024-09-30 at 9.13.36 PM

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-18 at 12.30.33 AM

BVNKF

New Hope For Mpox? How TNX-801 Could Meet The WHO&#39;s Vaccine Targets For A Safer, Single-Dose Solution

Untitled design - 2024-09-04T162950.621

As Research Into Pain Accelerates, A Newly Recognized Type Of Pain Comes To The Forefront – Tonix Targets It With FDA-Fast Track-Designated TNX-102 SL

Screenshot 2024-08-23 at 3.09.59 AM

Modern Twist To Centuries-Old Smallpox Vaccine Could Be Poised To Combat Deadly Mpox Strain As WHO Declares Global Emergency

Screenshot 2024-08-01 at 5.06.20 PM

FDA Recognizes Fibromyalgia As A &#39;Serious Condition&#39; And Fast-Tracks New Drug Candidate

Screenshot 2024-07-23 at 10.19.53 PM

Beyond &#34;One Bug, One Drug&#34; – Tonix Pharmaceuticals Secures Up To $34 Million In Funding From U.S. Department Of Defense To Develop Broad-Spectrum Antiviral

Screenshot 2024-07-10 at 9.08.28 PM

AXSM

A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath

Comments

Tonix Pharmaceuticals

Tonix Pharmaceuticals (TNXP) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌